In vivo activity of cefcapene proxetil in the experimental motel of mouse septicemia infected by bacteria

Wei Zhong,Yun Li,Yuan Lu,Man-ning Li,Jian Liu
DOI: https://doi.org/10.13461/j.cnki.cja.005143
2013-01-01
Abstract:Objective To evaluate the in vivo activity of cefcapene proxetil in the experimental therapy of mouse septicemia caused by clinical isolated pathogenic bacteria in recent years in China.Methods The mice were intraperitoneally injected with 0.5 mL minimum lethal dose(MLD) bacteria and experimental model of mouse septicemia was established.Cefcapene proxetil and cefpodoxime proxetil were each oral administered in a single dose.The survival of the infected mice were monitored for 7 days,and the 50%,95% effective dose(ED50,ED95) was determined by the BLISS method.Results The ED50 and ED95 of cefcapene proxetil against extended-spectrum beta-lactamase(ESBL) negative Escherichia coli,ESBL negative Klebsiella peumoniae,methicillin susceptibility Staphylococcus aureus(MSSA) and penicillin susceptibility Streptococcus pneumoniae were 0.27~8.08 mg·kg-1 and 2.31~25.45 mg·kg-1,which were almost the same as that of cefpodoxime proxetil.Conclusion Cefcapene proxetil showed a good in vivo activity for gram-positive and negative bacterial.
What problem does this paper attempt to address?